The survival time of antiphospholipid syndrome is usually closely related to the patient’s physical condition, the severity of the disease and whether the standardized diagnosis and treatment, and other factors, depending on the individual, there is no clear survival time, and it is recommended that the patient actively standardize the treatment.
Antiphospholipid syndrome is a non-inflammatory autoimmune disease characterized by recurrent arterial and venous thrombosis, habitual abortion, thrombocytopenia, and persistent high-titer positivity of antiphospholipid antibodies, and is most common in young people, with a male-to-female incidence ratio of 1:9, and the median age of females is 30.
Patients with antiphospholipid syndrome who are in good physical condition and have mild disease can generally control their disease well after active and standardized treatment, and their survival time will be longer; if the patients are in poor physical condition, have serious disease and are not treated actively and standardized, the prognosis of the disease is poor, and the survival time is shorter, and in severe cases, the patients may die in a short period of time.
Antiphospholipid syndrome patients under the guidance of the doctor to actively standardize the treatment, can effectively improve the prognosis of the disease, can improve the quality of life of patients in order to prolong the survival time. It is recommended that patients seek timely medical treatment and follow the doctor’s instructions to standardize the diagnosis and treatment.